Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. (22nd January 2020)

• Record Type: Journal Article
• Authors: Sobas, Marta; Rodriguez‐Veiga, Rebeca; Vellenga, Edo; Paluszewska, Monika; De la Serna, Javier; García‐Álvarez, Flor; Gil, Cristina; Brunet, Salut; Bergua, Juan; González‐Campos, Jose; Ribera, José María; Tormo, Mar; González, Marcos; Fernández, Isolda; Benavente, Celina; González‐Sanmiguel, Jose D.; Esteve, Jordi; Pérez‐Encinas, Manuel; Salamero, Olga; Manso, Felix; Lowenberg, Bob; Sanz, Miguel A.; Montesinos, Pau
• Is Part Of: European journal of haematology. Volume 104:Number 3(2020)
• Page Start: 162
• Page End: 169
• Publication Date: 2020-01-22
• Subjects: acute promyelocytic leukemia -- AIDA protocol -- obesity -- outcome; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.13346
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Objective: The obesity/overweight may have an influence on APL outcomes. Methods: This is the biggest multicentre analysis on 1320 APL patients treated with AIDA‐induction and risk‐adapted consolidation between 1996 and 2012. Patients body mass index (BMI) was classified as underweight (<18.5 kg/m 2 ), normal (18.5‐25 kg/m 2 ), overweight (25‐29.9 kg/m 2 ), and obese (≥30 kg/m 2 ) according to the World Health Organization (WHO) criteria. Results and conclusions: Relationship between male gender, older age, and other known laboratory abnormalities in overweight/obese patients was significant. The induction mortality rate was significantly higher in APL with BMI ≥25 vs BMI <25 (10% vs 6%; P = .04). APL patients with BMI ≥25 had a trend to lower OS (74% vs 80%; P = .06). However, in the multivariate analysis, BMI did not retain the independent predictive value ( P = .46). There was no higher incidence of differentiation syndrome with BMI ≥25, but there was a trend in obese. There was no difference in relapse rate according to the BMI. In summary, overweight/obesity does not represent an independent risk factor for APL outcomes. The influence of obesity in APL patients treated with chemotherapy‐free regimens remains to be established.